In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.
The investigators conducted a retrospective chart review of patients’ demographic and clinical data from 2005 to 2020.
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.
In this investigation, the second stage of the CHAMP phase 3 trial assessed the impact of prolonging drug administration for an extra 12 months on myopia control and the occurrence of myopia rebound upon cessation of dosing.
New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal
Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
David A Berntsen, OD, PhD, FAAO, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about axial growth after discontinuing soft multifocal contact lens wear in the BLINK2 study.
Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution
Research being presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, is examining novel interventions that could address the growth in myopia.
At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.
With the progression of MS, thinning of the retinal ganglion cell (RGC) complex is seen as well as a decrease in the amplitude of the pattern electroretinogram (pERG)
Deborah Ristvedt, DO, in her Controversies in Modern Eye Care presentation, discussed the evolution from traditional glaucoma treatments to novel therapies that target the trabecular meshwork and that aim to optimize IOP management without the need for multiple medications.
Inder Paul Singh, MD, highlights how early intervention, modern techniques, and reduced medication burden can improve outcomes and quality of life for patients with glaucoma in his presentation at the Controversies in Modern Eye Care conference.
Kelsey Roelofs, MD, shares some useful tips for identifying and diagnosing thyroid eye disease for attendees of the 18th Annual Controversies in Modern Eye Care symposium.
James A. Katz, MD, discussed evolving treatments for Demodex blepharitis, highlighting traditional methods like tea tree oil and microblepharoexfoliation as well as a newer FDA-approved therapy, and emphasizing the need to examine the upper eyelid carefully to diagnose the condition.
The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.
Hura highlighted some of the key takeaways from the Controversies in Modern Eye Care symposium where presenters and attendees shared their insights into the latest advancements in refractive surgery, retina care, and collaborative eye care.
Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.
More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.
Neda Nikpoor, MD, urges audience members to become more empowered in making small but meaningful, evidence-based changes in combating unconscious gender bias.
George O. Waring IV, MD, FACS, highlighted preliminary data from an open-label clinical trial, where his site was 1 of 4 in the US.
Deborah Gess Ristvedt, DO, shares highlights from her presentation and what these real-world cases mean for clinicians and their patients with glaucoma.
Program cochair Arjan Hura, MD, previews this year’s extended schedule with discussions on retina gene therapies, corneal endothelial diseases, and oculoplastics, along with hands-on experiences.
Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations at the ARVO annual conference in Seattle, Washington.
At this year's ASCRS meeting in Boston, Massachusetts, Shoham-Hazon, MD provided highlights from his two paper presentations.
At the 2024 ASCRS meeting, David M. Lubeck detailed highlights from his presentations on the minimally invasive glaucoma surgery (MIGS) space.
Annual conference to kick off May 5 in Emerald City.
At this year's ASCRS meeting in Boston, Massachusetts, Josefina Botta, MD, MSc, discussed her real-world experiences with the RayOne EMV toric lens.
At this year's ASCRS meeting Rom Kandavel, MD, of Colvard-Kandavel Eye Center in Los Angeles, California discussed the paper he presented at the meeting, which focused on IOP lowering and medication burden for patients who received the iStent inject.
